BANNOCKBURN, Ill., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent national provider of home and alternate site infusion services, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 in San Francisco. John Rademacher, Chief Executive Officer, and Mike Shapiro, Chief Financial Officer, are scheduled to present at 9:00am PT.
Webcast links and related presentation materials will be available online at https://investors.optioncarehealth.com.
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 7,500 team members including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at OptionCareHealth.com.
For Investor Inquiries:
Mike Shapiro, Chief Financial Officer
Option Care Health
312.940.2538
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$32.51 |
| Daily Change: | 0.10 0.31 |
| Daily Volume: | 3,092,261 |
| Market Cap: | US$5.160B |
October 30, 2025 July 30, 2025 April 29, 2025 February 26, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load